285 related articles for article (PubMed ID: 11854201)
1. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients.
Ang CW; Laman JD; Willison HJ; Wagner ER; Endtz HP; De Klerk MA; Tio-Gillen AP; Van den Braak N; Jacobs BC; Van Doorn PA
Infect Immun; 2002 Mar; 70(3):1202-8. PubMed ID: 11854201
[TBL] [Abstract][Full Text] [Related]
2. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.
Yuki N
J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies.
Prendergast MM; Moran AP
J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055
[TBL] [Abstract][Full Text] [Related]
4. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
Ang CW; De Klerk MA; Endtz HP; Jacobs BC; Laman JD; van der Meché FG; van Doorn PA
Infect Immun; 2001 Apr; 69(4):2462-9. PubMed ID: 11254608
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis.
Yuki N
Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987
[TBL] [Abstract][Full Text] [Related]
6. Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits.
Ang CW; Noordzij PG; de Klerk MA; Endtz HP; van Doorn PA; Laman JD
Infect Immun; 2002 Sep; 70(9):5081-5. PubMed ID: 12183556
[TBL] [Abstract][Full Text] [Related]
7. [Campylobacter jejuni enteritis and Guillain-Barré syndrome].
Yuki N
Rinsho Byori; 1999 Aug; 47(8):713-8. PubMed ID: 10511801
[TBL] [Abstract][Full Text] [Related]
8. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome?
Yuki N; Koga M; Hirata K
Acta Neurol Scand; 2000 Aug; 102(2):132-4. PubMed ID: 10949532
[TBL] [Abstract][Full Text] [Related]
9. Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barré syndrome.
Yuki N
Cell Mol Life Sci; 2000 Apr; 57(4):527-33. PubMed ID: 11130452
[TBL] [Abstract][Full Text] [Related]
10. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome.
Koga M; Takahashi M; Masuda M; Hirata K; Yuki N
Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes.
Godschalk PC; Kuijf ML; Li J; St Michael F; Ang CW; Jacobs BC; Karwaski MF; Brochu D; Moterassed A; Endtz HP; van Belkum A; Gilbert M
Infect Immun; 2007 Mar; 75(3):1245-54. PubMed ID: 17261613
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome.
Jacobs BC; Endtz HP; van der Meché FG; Hazenberg MP; de Klerk MA; van Doorn PA
J Neuroimmunol; 1997 Oct; 79(1):62-8. PubMed ID: 9357448
[TBL] [Abstract][Full Text] [Related]
13. Anti-ganglioside antibody and neuropathy: review of our research.
Yuki N
J Peripher Nerv Syst; 1998; 3(1):3-18. PubMed ID: 10959233
[TBL] [Abstract][Full Text] [Related]
14. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.
Yuki N
Lancet Infect Dis; 2001 Aug; 1(1):29-37. PubMed ID: 11871407
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies.
Islam Z; Gilbert M; Mohammad QD; Klaij K; Li J; van Rijs W; Tio-Gillen AP; Talukder KA; Willison HJ; van Belkum A; Endtz HP; Jacobs BC
PLoS One; 2012; 7(8):e43976. PubMed ID: 22952833
[TBL] [Abstract][Full Text] [Related]
16. Guillain-Barré syndrome and Fisher's syndrome following Campylobacter jejuni infection.
Yuki N; Miyatake T
Ann N Y Acad Sci; 1998 Jun; 845():330-40. PubMed ID: 9668366
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
Jacobs BC; Hazenberg MP; van Doorn PA; Endtz HP; van der Meché FG
J Infect Dis; 1997 Mar; 175(3):729-33. PubMed ID: 9041356
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.
Endtz HP; Ang CW; van Den Braak N; Duim B; Rigter A; Price LJ; Woodward DL; Rodgers FG; Johnson WM; Wagenaar JA; Jacobs BC; Verbrugh HA; van Belkum A
J Clin Microbiol; 2000 Jun; 38(6):2297-301. PubMed ID: 10834992
[TBL] [Abstract][Full Text] [Related]
19. Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of genomic similarity.
Taboada EN; van Belkum A; Yuki N; Acedillo RR; Godschalk PC; Koga M; Endtz HP; Gilbert M; Nash JH
BMC Genomics; 2007 Oct; 8():359. PubMed ID: 17919333
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome.
Bowes T; Wagner ER; Boffey J; Nicholl D; Cochrane L; Benboubetra M; Conner J; Furukawa K; Furukawa K; Willison HJ
Infect Immun; 2002 Sep; 70(9):5008-18. PubMed ID: 12183547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
